New AML combo trial halted early after enrolling 15 patients
Disease control
Terminated
This study tested a new drug called CWP232291 combined with standard chemotherapy (cytarabine) in people whose acute myeloid leukemia (AML) had returned or stopped responding to treatment. The goal was to find a safe dose and see if the combination could shrink or eliminate the c…
Phase: PHASE1, PHASE2 • Sponsor: JW Pharmaceutical • Aim: Disease control
Last updated May 12, 2026 13:40 UTC